Anthropic reveals its one-person drug startup deal and Claude-run research workflow
Mithril's founder used Claude to coordinate 11 outside labs; the newly disclosed July acquisition brings two rare-disease programs inside Anthropic.
Anthropic has disclosed that it acquired Mithril Medicine, a drug startup with one full-time employee, and is using its programs to test how much research one scientist can direct with Claude. The company’s October 27 update makes the deal and workflow public; its detailed case study says the acquisition happened in July. This is a new disclosure of earlier work, not an acquisition completed this week.
Founder Cody Tranbarger is continuing programs for two rare forms of muscular dystrophy at Anthropic. According to the company, he used Claude to manage contracts, logistics and experiments across 11 external laboratories, alongside part-time consultants. Anthropic says Mithril moved one treatment idea to promising mouse results in less than 18 months. That is the company’s account of the program, not a controlled measurement of how much faster Claude made it.
The accompanying October 26 technical report, explicitly marked not peer reviewed, describes bispecific antibodies designed to restore a missing connection around muscle fibers in LAMA2-related congenital muscular dystrophy. It reports laboratory experiments and a mouse proof of principle. These results support further investigation; they do not show that the treatment is safe or effective in people.
The broader update covers six partners, including BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. Their case studies range from molecule design to manufacturing paperwork and clinical-trial planning. The concrete pitch is that AI can handle operational and scientific work throughout a drug program, extending beyond proposing molecules.
Anthropic says most of the work remains preclinical. If the candidates continue to hold up, it expects a Mithril drug could enter human trials as soon as late 2028. That is a conditional target, not an approved treatment or a promised cure. The immediate news is the emergence of an in-house drug-development effort and a documented experiment in organizing small research teams around Claude.